Gilbert Wagener
Chief Tech/Sci/R&D Officer at PHARNEXT SCA
Profile
Gilbert Wagener is currently the Chief Medical Officer at Pharnext SA since 2023.
Prior to this, he held the same position at Cell2B - Advanced Therapeutics SA and Ixaka Ltd.
Dr. Wagener holds a doctorate from Erasmus University Rotterdam and Philipps University of Marburg, and an MBA from the University of Basel.
Gilbert Wagener active positions
| Companies | Position | Start |
|---|---|---|
| PHARNEXT SCA | Chief Tech/Sci/R&D Officer | 15/06/2023 |
Former positions of Gilbert Wagener
| Companies | Position | End |
|---|---|---|
Ixaka Ltd.
 Ixaka Ltd. BiotechnologyHealth Technology Ixaka Ltd. engages in the development of advanced cell-based therapeutics for the treatment of critical limb ischemia. The company was founded by Gaby Salem and Vicente Saez Gonzalez in 2015 and is headquartered in London, the United Kingdom. | Chief Tech/Sci/R&D Officer | - |
Cell2B - Advanced Therapeutics SA
 Cell2B - Advanced Therapeutics SA BiotechnologyHealth Technology Cell2B - Advanced Therapeutics SA engages in the development of stem cell therapies for immune and inflammatory diseases. Its pipeline consists of cord blood unit expansion and anti-rejection medications. The company was founded by Daniela Couto, David Braga Malta, Francisco dos Santos, and Pedro Andrade in 2011 and is headquartered in Cantanhede, Portugal. | Chief Tech/Sci/R&D Officer | - |
Training of Gilbert Wagener
| Philipps University of Marburg | Doctorate Degree |
| University of Basel | Masters Business Admin |
| Erasmus University Rotterdam | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| PHARNEXT SCA | Health Technology |
| Private companies | 2 |
|---|---|
Cell2B - Advanced Therapeutics SA
Cell2B - Advanced Therapeutics SA BiotechnologyHealth Technology Cell2B - Advanced Therapeutics SA engages in the development of stem cell therapies for immune and inflammatory diseases. Its pipeline consists of cord blood unit expansion and anti-rejection medications. The company was founded by Daniela Couto, David Braga Malta, Francisco dos Santos, and Pedro Andrade in 2011 and is headquartered in Cantanhede, Portugal. | Health Technology |
Ixaka Ltd.
Ixaka Ltd. BiotechnologyHealth Technology Ixaka Ltd. engages in the development of advanced cell-based therapeutics for the treatment of critical limb ischemia. The company was founded by Gaby Salem and Vicente Saez Gonzalez in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Gilbert Wagener
